Drugs that contain Ethinyl Estradiol; Norethindrone Acetate
1. Lo Loestrin Fe patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5552394 | APIL | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul, 2014
(9 years ago) | |
| US7704984 | APIL | Extended estrogen dosing contraceptive regimen |
Feb, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 21, 2013 |
Market Authorisation Date: 21 October, 2010
Treatment: Lo loestrin fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception
Dosage: TABLET;ORAL
LO LOESTRIN FE family patents
2. Lo Minastrin Fe patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5552394 | APIL | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul, 2014
(9 years ago) | |
| US6667050 | APIL | Chewable oral contraceptive |
Apr, 2019
(5 years ago) | |
| US7704984 | APIL | Extended estrogen dosing contraceptive regimen |
Feb, 2029
(4 years from now) | |
Market Authorisation Date: 24 July, 2013
Treatment: Prevention of pregnancy
Dosage: TABLET, CHEWABLE, TABLET;ORAL
LO MINASTRIN FE family patents
3. Loestrin 24 Fe patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5552394 | TEVA BRANDED PHARM | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul, 2014
(9 years ago) | |
Market Authorisation Date: 17 February, 2006
Treatment: Prevention of pregnancy
Dosage: TABLET;ORAL
LOESTRIN 24 FE family patents
4. Minastrin 24 Fe patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5552394 | APIL | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul, 2014
(9 years ago) | |
| US6667050 | APIL | Chewable oral contraceptive |
Apr, 2019
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | May 08, 2016 |
Market Authorisation Date: 08 May, 2013
Treatment: Prevention of pregnancy
Dosage: TABLET;ORAL
MINASTRIN 24 FE family patents
5. Taytulla patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5552394 | APIL | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul, 2014
(9 years ago) | |
| US6652880 | APIL | Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants |
Mar, 2020
(4 years ago) | |
Market Authorisation Date: 19 April, 2013
Treatment: Prevention of pregnancy
Dosage: CAPSULE;ORAL
TAYTULLA family patents